Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide6 min read

DirectMeds Cost 2026: $249 Sublingual, $297 Injections

DirectMeds lists $249/month for sublingual semaglutide and $297/month for injections. How that compares with other GLP-1 providers, and what to confirm first.

Updated September 15, 2026

Medically reviewed on

How we review

Key takeaways

  • DirectMeds lists $249/month for sublingual semaglutide and $297/month for injections (read Nov 18, 2026), with no subscriptions, the doctor review and free 1-2 day shipping; cancel anytime.
  • Tirzepatide patients: DirectMeds publishes no tirzepatide price. The cheaper published prices are welludr $71, embody $99 and altRx $149.
  • Semaglutide patients: five providers list less per month - welludr $41, embody $49, altRx $89, Medvi $99 promo, HealthRx $125 after a $39 first month - a $1,488-$2,496 annual difference at $249.
  • 6- and 12-month bulk plans are offered but not priced on the page, so a long-plan rate cannot be quoted.

What the page prices, and what it does not

At a glanceDirectMeds lists plans from $249/month for sublingual semaglutide and $297/month for injections, with no subscriptions. Included: the doctor review, the medication, free 1-2 day shipping. 6- and 12-month bulk plans are offered but not priced. Cancel anytime.

Before November 18, 2026 the page showed a different, flat price that is no longer there, so every comparison here uses $249 and $297. What is left to decide: which format, and whether $249 is the right number for you.

How $249 compares

If you're on semaglutide: $249 is above five providers - welludr $41, embody $49, altRx $89, Medvi $99 promo, HealthRx $125 after a $39 first month - a $1,488-$2,496 annual difference. Unless the drops format is what you're buying, the budget tier serves semaglutide patients better.

If you're on tirzepatide: DirectMeds publishes no price for it. The published tirzepatide prices are welludr $71, embody $99, altRx $149, Medvi $166 promo, HealthRx $199, TrimRx $259 and SHED $299.

ProviderSemaglutideTirzepatide
welludr$41/mo$71/mo
embody$49/mo$99/mo
altRx$89/mo$149/mo
Medvi$99/mo promo (reg. $199)$166/mo promo (reg. $299)
HealthRx$125/mo*$199/mo*
SHED$199/mo$299/mo
DirectMeds$249/mo (sublingual)Not published

*After a $39 first month. Choosing between the two medications in the first place: tirzepatide vs semaglutide.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

Questions the pricing page leaves open

Two things the page does not say. First, whether the price changes as the dose rises: standard titration moves you up several dose levels across the first months, so ask whether $249 holds at each step. Second, which medication the $297 injection plan covers: the page names none, which is why we list no injectable price for either medication. Ask both before you pay, and ask what the 6- and 12-month bulk plans cost.

How much extra do the needle-free drops cost?

For drops customers the comparison table above is moot - nobody else sells the format. The honest math: against the cheapest injectable (welludr, $41), choosing drops at DirectMeds costs $208/month more. If needle aversion would otherwise keep you off treatment entirely, that is the price of starting. If you'd tolerate injections fine, the premium buys convenience, and the budget tier deserves your look first.

→ Full DirectMeds review with format details

This article is general information, not medical advice. Prices as listed at the time of writing - confirm current pricing on the provider's site.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)